The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis

CONCLUSIONS: Within this specific population, GLP-1 RAs exhibit a notable association with substantial reductions in HbA1c, FBG, and body weight. The administration of these medications is concurrent with an elevated incidence of side effects, which are predominantly gastrointestinal and tolerable.TRIAL REGISTRATION: PROSPERO identifier: CRD42023393020.PMID:38659064 | DOI:10.1186/s13098-024-01337-5

Source: Atherosclerosis - April 24, 2024 Category: Cardiology Authors: Louise Buonalumi Tacito Yugar Luis Gustavo Sedenho-Prado Isadora Maria Castilho da Silva Ferreira Cleide Aparecida Moreira Silva Andrei C Sposito Cintia Cercato Source Type: research